Rigel Pharmaceuticals Inc
RIGL44.010USD
-0.630-1.41%
Cierre 12/26, 16:00（ET）Cotizaciones retrasadas 15 min
798.52MCap. mercado
6.94P/E TTM
Más Datos de Rigel Pharmaceuticals Inc Compañía
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Información de Rigel Pharmaceuticals Inc
Símbolo de cotizaciónRIGL
Nombre de la empresaRigel Pharmaceuticals Inc
Fecha de salida a bolsaNov 29, 2000
Director ejecutivoRodriguez (Raul R)
Número de empleados162
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 29
Dirección- -
Ciudad- -
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
País- -
Código postal- -
Teléfono- -
Sitio Web- -
Símbolo de cotizaciónRIGL
Fecha de salida a bolsaNov 29, 2000
Director ejecutivoRodriguez (Raul R)
Ejecutivos de Rigel Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
9.38K
+36.36%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: vie., 5 de dic
Actualizado: vie., 5 de dic
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
8.17%
The Vanguard Group, Inc.
5.75%
Armistice Capital LLC
3.99%
Acadian Asset Management LLC
3.78%
Marshall Wace LLP
3.31%
Otro
75.00%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
8.17%
The Vanguard Group, Inc.
5.75%
Armistice Capital LLC
3.99%
Acadian Asset Management LLC
3.78%
Marshall Wace LLP
3.31%
Otro
75.00%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
35.17%
Investment Advisor/Hedge Fund
27.88%
Hedge Fund
16.53%
Research Firm
4.76%
Individual Investor
2.62%
Pension Fund
0.50%
Bank and Trust
0.16%
Venture Capital
0.08%
Insurance Company
0.03%
Otro
12.27%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
291
14.62M
80.57%
-798.43K
2025Q2
290
14.23M
79.32%
-22.43K
2025Q1
295
14.90M
83.36%
+888.64K
2024Q4
281
12.77M
72.51%
-849.60K
2024Q3
291
12.41M
70.53%
-421.54K
2024Q2
303
10.88M
61.98%
-2.99M
2024Q1
319
11.57M
65.99%
-3.84M
2023Q4
326
11.03M
63.24%
-4.70M
2023Q3
343
11.50M
66.01%
-5.45M
2023Q2
356
11.96M
68.88%
-4.98M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
1.41M
7.85%
-63.90K
-4.34%
Jun 30, 2025
The Vanguard Group, Inc.
1.05M
5.87%
+24.80K
+2.41%
Jun 30, 2025
Armistice Capital LLC
1.60M
8.92%
+84.00K
+5.54%
Jun 30, 2025
Acadian Asset Management LLC
623.00K
3.47%
+57.96K
+10.26%
Jun 30, 2025
Marshall Wace LLP
368.95K
2.06%
+157.20K
+74.24%
Jun 30, 2025
Capitolis Liquid Global Markets LLC
591.55K
3.3%
-101.55K
-14.65%
Jun 30, 2025
State Street Investment Management (US)
600.18K
3.35%
-36.85K
-5.79%
Jun 30, 2025
Renaissance Technologies LLC
236.45K
1.32%
+35.30K
+17.55%
Jun 30, 2025
Geode Capital Management, L.L.C.
415.61K
2.32%
+4.44K
+1.08%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
1.17%
Inspire Fidelis Multi Factor ETF
0.92%
Zacks Small/Mid Cap ETF
0.88%
First Trust Dow Jones Select MicroCap Index Fund
0.87%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.81%
Janus Henderson Small Cap Growth Alpha ETF
0.71%
First Trust Active Factor Small Cap ETF
0.24%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.24%
ALPS Medical Breakthroughs ETF
0.23%
ALPS Barron's 400 ETF
0.21%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción1.17%
Inspire Fidelis Multi Factor ETF
Proporción0.92%
Zacks Small/Mid Cap ETF
Proporción0.88%
First Trust Dow Jones Select MicroCap Index Fund
Proporción0.87%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporción0.81%
Janus Henderson Small Cap Growth Alpha ETF
Proporción0.71%
First Trust Active Factor Small Cap ETF
Proporción0.24%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proporción0.24%
ALPS Medical Breakthroughs ETF
Proporción0.23%
ALPS Barron's 400 ETF
Proporción0.21%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Fecha
Tipo
Relación
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Rigel Pharmaceuticals Inc?
Los cinco principales accionistas de Rigel Pharmaceuticals Inc son:
BlackRock Institutional Trust Company, N.A. posee 1.41M acciones, lo que representa el 7.85% del total de acciones.
The Vanguard Group, Inc. posee 1.05M acciones, lo que representa el 5.87% del total de acciones.
Armistice Capital LLC posee 1.60M acciones, lo que representa el 8.92% del total de acciones.
Acadian Asset Management LLC posee 623.00K acciones, lo que representa el 3.47% del total de acciones.
Marshall Wace LLP posee 368.95K acciones, lo que representa el 2.06% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 1.41M acciones, lo que representa el 7.85% del total de acciones.
The Vanguard Group, Inc. posee 1.05M acciones, lo que representa el 5.87% del total de acciones.
Armistice Capital LLC posee 1.60M acciones, lo que representa el 8.92% del total de acciones.
Acadian Asset Management LLC posee 623.00K acciones, lo que representa el 3.47% del total de acciones.
Marshall Wace LLP posee 368.95K acciones, lo que representa el 2.06% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Rigel Pharmaceuticals Inc?
Los tres principales tipos de accionista de Rigel Pharmaceuticals Inc son:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Armistice Capital LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Armistice Capital LLC
¿Cuántas instituciones poseen acciones de Rigel Pharmaceuticals Inc (RIGL)?
A fecha de 2025Q3, 291 instituciones poseen acciones de Rigel Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 14.62M, lo que representa el 80.57% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en 1.25%.
¿Cuál es la mayor fuente de ganancias de Rigel Pharmaceuticals Inc?
El --, el segmento empresarial -- generó la ganancia más alta para Rigel Pharmaceuticals Inc, ascendiendo a -- y representando el --% de la ganancia total.
